RNXT
RenovoRx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.16
+1.75%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.15
From 52W high−53.97%
Volume288381.00
Market cap$52.35M
P/E (TTM)—
P/S (TTM)26.5x
Div yield—
Key dataOct 19, 2026
Open
$1.15
From 52W high
−53.97%
Volume
288381.00
Market cap
$52.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
P/E (TTM)
—
RSI (14)
34.7
MomentumView details →
1D Return
+1.75%
YTD Return
+38.67%
SummaryUpdated Jun 1, 2026
RenovoRx, Inc. (NASDAQ:RNXT) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Los Altos, California. The company went public in August 2021 and focuses on developing innovative therapies for treating solid tumors, particularly pancreatic cancer. RenovoRx has developed a unique approach combining drug delivery devices with chemotherapy medications to improve treatment outcomes while reducing side effects for cancer patients.
Similar companies
Latest newsMore news →
RenovoRx, Inc. announced that the first patient was enrolled in the University of Vermont-sponsored PRISM-TAMP trial, which is evaluating TAMP before surgical resection in borderline resectable pancreatic cancer.12d agoRenovoRx announced a peer-reviewed publication highlighting the potential of its TAMP platform to improve chemotherapeutic delivery for locally advanced pancreatic cancer.18d agoRenovoRx received written notification from Nasdaq confirming it regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.59d ago